GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (LTS:0QFK) » Definitions » Cyclically Adjusted PB Ratio

Celyad Oncology (LTS:0QFK) Cyclically Adjusted PB Ratio : 0.06 (As of Jun. 06, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Cyclically Adjusted PB Ratio?

As of today (2024-06-06), Celyad Oncology's current share price is €0.368. Celyad Oncology's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec22 was €5.85. Celyad Oncology's Cyclically Adjusted PB Ratio for today is 0.06.

The historical rank and industry rank for Celyad Oncology's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0QFK' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.15
Current: 0.05

During the past 12 years, Celyad Oncology's highest Cyclically Adjusted PB Ratio was 0.15. The lowest was 0.00. And the median was 0.00.

LTS:0QFK's Cyclically Adjusted PB Ratio is ranked better than
92.44% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs LTS:0QFK: 0.05

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Celyad Oncology's adjusted book value per share data of for the fiscal year that ended in Dec22 was €0.191. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €5.85 for the trailing ten years ended in Dec22.

Shiller PE for Stocks: The True Measure of Stock Valuation


Celyad Oncology Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Celyad Oncology's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Cyclically Adjusted PB Ratio Chart

Celyad Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.46 0.71 0.09

Celyad Oncology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 - - 0.09 -

Competitive Comparison of Celyad Oncology's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Celyad Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celyad Oncology's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Cyclically Adjusted PB Ratio falls into.



Celyad Oncology Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Celyad Oncology's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.368/5.85
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec22 is calculated as:

For example, Celyad Oncology's adjusted Book Value per Share data for the fiscal year that ended in Dec22 was:

Adj_Book=Book Value per Share/CPI of Dec22 (Change)*Current CPI (Dec22)
=0.191/126.5776*126.5776
=0.191

Current CPI (Dec22) = 126.5776.

Celyad Oncology Annual Data

Book Value per Share CPI Adj_Book
201312 2.668 99.462 3.395
201412 3.790 99.086 4.842
201512 11.969 100.572 15.064
201612 9.758 102.614 12.037
201712 4.817 104.804 5.818
201812 4.655 107.252 5.494
201912 3.272 108.065 3.833
202012 2.223 108.511 2.593
202112 1.931 114.705 2.131
202212 0.191 126.578 0.191

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Celyad Oncology  (LTS:0QFK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Celyad Oncology Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Celyad Oncology (LTS:0QFK) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (LTS:0QFK) Headlines

No Headlines